Diagnostics News and Research

RSS

Opinions: Using taxes to reduce poverty; fighting TB; meeting global food demands

To improve living standards and create jobs," African governments "need to provide their citizens with better health care, better education, more infrastructure. How to pay for this - in a way that is both fair and efficient - is a question that all governments face," Mark Plant, deputy director of the IMF's African Department, writes in a BusinessDay opinion piece where he describes how increased tax revenues in several African countries have led to "in-roads into poverty reduction."

25 Mar 2011

FDA approves Medtronic's Consulta and Syncra pacemaker systems

Medtronic, Inc. today announced that the U.S. Food & Drug Administration has approved its Consulta and Syncra cardiac resynchronization therapy-pacemaker systems.

25 Mar 2011

HDL, BG Medicine to offer galectin-3 testing services for patients with heart failure

Health Diagnostic Laboratory, Inc. and BG Medicine, Inc., announced today an agreement under which HDL, Inc. will offer galectin-3 testing services based on the BG Medicine Galectin-3 Test.

25 Mar 2011

Imaging with voltage-sensitive dye captures real-time brain dynamics

The dye incorporates in the brain cells' membrane and changes fluorescence whenever these receive or send electrical signals. Hence, high resolution camera systems allow to simultaneously capture activities of millions of nerve cells across several square millimeters across the brain.

24 Mar 2011

New insights into multiple myeloma research

Scientists have unveiled the most comprehensive picture to date of the full genetic blueprint of multiple myeloma, a form of blood cancer. A study of the genomes from 38 cancer samples has yielded new and unexpected insights into the events that lead to this form of cancer and could influence the direction of multiple myeloma research.

24 Mar 2011

Aptiv Solutions, Cancer Genetics partner to deliver comprehensive solutions for clinical trials in oncology

Aptiv Solutions and Cancer Genetics, Inc. (CGI) have formed a strategic partnership focused on delivering comprehensive solutions to biopharmaceutical and medical device firms conducting clinical trials for oncology therapeutics.

24 Mar 2011

Contrast agent for tumor diagnostics

X-rays are not the only way: visible and especially infrared light can also be used to image human tissue. The effectiveness of optical imaging processes can be significantly improved with suitable dyes used as contrast agents. In the journal Angewandte Chemie, a team led by Wenbin Lin at the University of North Carolina (Chapel Hill, USA) has now introduced a novel contrast agent that marks tumor cells in vitro. The dye is a phosphorescent ruthenium complex incorporated into nanoparticles of a metal–organic coordination polymer, which allows an extraordinarily high level of dye loading.

23 Mar 2011

Asuragen introduces CE-mark approved AmplideX FMR1 PCR Kit

Asuragen, Inc. announced that they have achieved CE-marking and commercial launch in Europe of the AmplideX FMR1 PCR Kit for the detection of CGG repeats in the fragile X mental retardation gene.

23 Mar 2011

Abbott receives CE-Mark for new qualitative PCR-based HIV-1 test

Abbott (NYSE: ABT) announced today that it has received CE-Mark for a new qualitative PCR-based HIV-1 test that produces highly accurate results from dried blood spot and plasma specimens. The new assay is a long-awaited diagnostic tool for health officials in African nations and other resource-limited areas to detect HIV-1 infected infants at early stages and begin treatment when success is more likely.

21 Mar 2011

Quest Diagnostics proposes $1,250,000,000 senior notes offering

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, announced today that it intends to offer $1,250,000,000 in aggregate principal amount of four series of senior notes in a public offering made under a shelf registration statement filed with the Securities and Exchange Commission, subject to market and other conditions.

From Quest Diagnostics 21 Mar 2011

New synchrotron-based imaging technique offers more detailed chemical images

With intensity a million times brighter than sunlight, a new synchrotron-based imaging technique offers high-resolution pictures of the molecular composition of tissues with unprecedented speed and quality. Carol Hirschmugl, a physicist at the University of Wisconsin-Milwaukee (UWM), led a team of researchers from UWM, the University of Illinois at Urbana-Champaign and University of Illinois at Chicago (UIC) to demonstrate these new capabilities.

21 Mar 2011

The Lancet publishes Oceana's Solesta injectable gel study results against fecal incontinence

Oceana Therapeutics, a global company focused on acquiring, developing and commercializing best-in-class specialty therapeutics, today announced the publication of results from a randomized-controlled clinical trial of the bulking agent, NASHA DX, a dextranomer suspended in stabilized, which was injected into the submucosa of the anal canal in patients with fecal incontinence.

19 Mar 2011

Quest Diagnostics enters definitive merger agreement to acquire Celera for $8 per share

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, and Celera Corporation, one of the world's pioneers in genetic diagnostics discovery and development, announced today that they have entered into a definitive merger agreement under which Quest Diagnostics will acquire Celera for $8 per share, representing a transaction value of approximately $344 million, net of $327 million in acquired cash and short-term investments.

From Quest Diagnostics 18 Mar 2011

GHDX presents Oncotype DX breast cancer test study results at St. Gallen conference

Genomic Health, Inc. today announced results from nine studies utilizing the Oncotype DX test in early-stage breast cancer patients at the 12th Annual St. Gallen International Breast Cancer Conference in St. Gallen, Switzerland.

18 Mar 2011

New detector technologies capable of reducing radiation dose from BSGI/MBI studies by 75%

A new study by Craig Thiessen, M.D., Director of Radiology for West Houston Radiology L.L.P. and North Cypress Medical Center in Houston, presented this week at the National Consortium of Breast Centers Annual Meeting, found the improved photon sensitivity of new detector technologies such as PSPMTs and CZT should be capable of reducing the radiation dose patient receive from BSGI/MBI studies by 75%.

18 Mar 2011

Modified mRNA raises hope for safe and effective cancer drugs

Modern gene therapies raise hopes of combating many diseases until now considered terminal. Nowadays, however, the methods are expensive and carry a risk of severe complications.

18 Mar 2011

Transcranial LED-based light therapy improves cognitive function in traumatic brain injury patients

At-home, daily application of light therapy via light-emitting diodes (LEDs) placed on the forehead and scalp led to improvements in cognitive function and post-traumatic stress disorder in patients with a traumatic brain injury (TBI), according to a groundbreaking study published in Photomedicine and Laser Surgery, a peer-reviewed journal published by Mary Ann Liebert, Inc.

18 Mar 2011

Quest Diagnostics ColoVantage molecular colorectal cancer detection test receives New York State approval

Quest Diagnostics Incorporated, the world's leading cancer diagnostics company, today announced that its ColoVantage test has been approved by New York State's Department of Health for testing on samples of patients in the state. It is believed to be the first molecular colorectal cancer detection method that employs a venal blood specimen to be approved by the state.

From Quest Diagnostics 18 Mar 2011

Sports medicine physician suggests cardiac screening for young athletes requires augmentation of existing diagnostics to achieve greater accuracy, become cost-effective

Sports medicine physician Steve Watts says cardiac screening for young athletes is useful in preventing sudden cardiac death and suggests new diagnostics have the potential to add value and change the debate about the viability of cardiac screening for young athletes in the United States.

17 Mar 2011

Skyline Diagnostics launches unique test to detect patients with AML

Each year over eight million people die of cancer worldwide. Patients' chances of survival vary widely: depending on the type of cancer involved, the stage at which it is diagnosed and the speed with which appropriate treatment is launched.

17 Mar 2011

Diagnostics News and Research

Opinions: Using taxes to reduce poverty; fighting TB; meeting global food demands

FDA approves Medtronic's Consulta and Syncra pacemaker systems

HDL, BG Medicine to offer galectin-3 testing services for patients with heart failure

Imaging with voltage-sensitive dye captures real-time brain dynamics

New insights into multiple myeloma research

Aptiv Solutions, Cancer Genetics partner to deliver comprehensive solutions for clinical trials in oncology

Contrast agent for tumor diagnostics

Asuragen introduces CE-mark approved AmplideX FMR1 PCR Kit

Abbott receives CE-Mark for new qualitative PCR-based HIV-1 test

Quest Diagnostics proposes $1,250,000,000 senior notes offering

New synchrotron-based imaging technique offers more detailed chemical images

The Lancet publishes Oceana's Solesta injectable gel study results against fecal incontinence

Quest Diagnostics enters definitive merger agreement to acquire Celera for $8 per share

GHDX presents Oncotype DX breast cancer test study results at St. Gallen conference

New detector technologies capable of reducing radiation dose from BSGI/MBI studies by 75%

Modified mRNA raises hope for safe and effective cancer drugs

Transcranial LED-based light therapy improves cognitive function in traumatic brain injury patients

Quest Diagnostics ColoVantage molecular colorectal cancer detection test receives New York State approval

Sports medicine physician suggests cardiac screening for young athletes requires augmentation of existing diagnostics to achieve greater accuracy, become cost-effective

Skyline Diagnostics launches unique test to detect patients with AML

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News